Results 81 to 90 of about 21,749 (235)
Diabetes, Metabolic Syndrome and Obesity, 2023 Min Sun,1,2 Lei Gao,1 Hongmei Bai,1 Weiwei Hu,1 Xiaofang Zhang,1 Jin Xiao,1 Xiangliang Deng,1 Hongmei Tao,1 Ping Ge,2 Yuhong Qin,1,* Dongying Zhang1,* 1Department of Cardiovascular Medicine, The First Affiliated Hospital of Chongqing Medical ...
Sun M +10 more
doaj
ESC Heart Failure, Volume 12, Issue 2, Page 1346-1357, April 2025.Abstract Aims Iron deficiency (ID) is prevalent in chronic heart failure (HF) but lacks a consensus definition. This study evaluates the prevalence and the prognostic impact of ID using different criteria on all‐cause and cardiovascular mortality, as well as first hospitalization for HF in patients with new‐onset chronic HF.
Abdullahi Ahmed Mohamed +12 more
wiley +1 more source
Correlation of NT-proBNP Levels with Outcome in Patients of Acute Decompensated Heart Failure
Indian Journal of Medical SpecialitiesBackground: Acute decompensated heart failure (ADHF) is a significant contributor to morbidity and mortality globally, particularly in resource-limited settings like India.
Dheeraj Balotia +4 more
doaj +1 more source
Health Technology Assessment, 2017 Background: Heart failure (HF) affects around 500,000 people in the UK. HF medications are frequently underprescribed and B-type natriuretic peptide (BNP)-guided therapy may help to optimise treatment.
Maria Pufulete +13 more
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1386-1397, April 2025.Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira +12 more
wiley +1 more source
Cardiologia HungaricaHeart failure (HF) is currently one of the most important public health problems. Heart failure with preserved ejection fraction (HFpEF) is a highly heterogeneous disease characterized by normal or near-normal left ventricular ejection fraction ...
Arnold Péter Ráduly +3 more
doaj +1 more source
Linezolid-Induced Pancytopenia in Patients Using Dapagliflozin: A Case Series
Infection and Drug Resistance, 2022 Meng Mei Li,1 Wen Cheng Shen,2 Yu Jin Li,1 Jun Teng1 1Qingdao Central Hospital, The Second Affiliated Hospital of Medical College of Qingdao University, Qingdao, People’s Republic of China; 2Department of Emergency, Qingdao Municipal Hospital (Group ...
Li MM, Shen WC, Li YJ, Teng J
doaj
Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine
ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi +3 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1132-1140, April 2025.Abstract The main purpose of this project was to capture experts' opinion on hyperkalaemia management and form best practice recommendations for cardiorenal patients in Greece. A steering committee of nephrologists and cardiologists developed 37 statements. An online questionnaire completed by 32 experts in cardiorenal management in Greece.
Christina Chrysohoou +3 more
wiley +1 more source
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source